Johnson & Johnson Reports THOR Overall Survival Data for Balversa in Bladder Cancer

Johnson & Johnson today presented overall survival data from the Phase 3 THOR trial evaluating Balversa (erdafitinib) versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with FGFR alterations. The data showed a significant improvement in overall survival with Balversa, with a median overall survival of 12.1 months compared to 7.8 months with chemotherapy.